Tetraphase

Tetraphase is a biopharmaceutical company focused on developing and commercializing novel tetracycline therapies to treat life-threatening conditions.

[Tetraphase @Tetraphase]

Thank you, Dr. Lodise for shedding light on the overuse of antipseudomonal β-lactams & fluoroquinolones among patients with cIAI at low risk for treatment failure or death.

This should encourage the review of treatment protocols in patients with cIAI.

https://t.co/x1YYL7bnLy

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

A NEW 🔥study #ofid @lodise_tom
Evaluation Adult Hospitalized Pts with Lower Risk CA cIAI
The most common diagnosis was acute appendicitis with peritonitis
Overuse of anti-pseudomonal β-lactams 😳
54% received TZP, 20% FQs Ceftriaxone 11% #IDTwitter
https://t.co/GQ2ZHL0aqo

[Tetraphase @Tetraphase]

Beckman Coulter has introduced a MicroScan Panel containing eravacycline as part of its Select Series Panels focusing on MDROs.
For more information, download Neg Urine Combo 89 and 90 Panels:
https://t.co/zuEaiBIivA

For information on #eravacycline go to https://t.co/WTpyJblnDO

[Tetraphase @Tetraphase]

(2/2)
the issue of MDR Gram-negative bacteria in cIAIs and potential new treatment options.

https://t.co/MqB5jn0IuH

[Tetraphase @Tetraphase]

(1/2)
Complicated intraabdominal infections (cIAIs) are one of the leading causes of emergency surgery and ICU admission.

Dr. Montravers and his colleagues have written an excellent review on the treatment of cIAIs highlighting...

[Tetraphase @Tetraphase]

Thank you, Contagion for highlighting the ongoing study by Hwang et al of #Eravacycline in the OPAT setting. Please see https://t.co/6udXptSO4D for additional information.

[Contagion @Contagion_Live]

#Eravacycline Realizes Successful Clinical Endpoint in #OPAT Facilities according to @MAD_ID_ASP

https://t.co/8V7zH92PSy

[Tetraphase @Tetraphase]

See the review on #eravacycline, a novel tetracycline that exhibits in vitro activity against various gram-negative, gram-positive aerobic and anaerobic pathogens https://t.co/oIPq8wnzb9 To learn more, head over to https://t.co/pHGjYc9em1”

[Tetraphase @Tetraphase]

@BCILifeSciences includes eravacycline on Gram-negative combo panel, NUC90 (C48640). The panel and updated software are available for order: https://t.co/IytmWJKTZE

[Tetraphase @Tetraphase]

https://t.co/5epVaEdlTd

[Tetraphase @Tetraphase]

The AAC publishes eravacycline 2013 – 2017 surveillance data as companion pieces for Gram-negative and Gram-positive bacteria. Both studies highlight the broad in vitro activity of eravacycline, including against MDR pathogens
https://t.co/5epVaEdlTd https://t.co/hYFdogtJVl

[Tetraphase @Tetraphase]

Excited to be a part of the @ASHP learning community at #ASHP2019! Checking out independent real-world data on #eravacycline at posters 7-065, 2-011, 13-238.

[Tetraphase @Tetraphase]

Great editorial on the impact of unnecessarily delaying implementation of cleared testing devices on treatment for patients in need.

[JClinMicro EIC @JClinMicro]

Bringing Antimicrobial Susceptibility Testing for New Drugs into the Clinical Laboratory: Removing Obstacles in Our Fight against Multidrug-Resistant Pathogens

https://t.co/7DtuBhUzxC @ASMicrobiology #ASMClinMicro

[Tetraphase @Tetraphase]

Pleased to have collaborated with several great companies, including BioMerieux, to provide testing options for eravacycline.

[Mark Miller @biomerieuxcmo]

What a year @biomerieux developing pivotal Etests to help labs/clinicians fight antimicrobial resistant (AMR) infections. In 2019, FDA-cleared Etests for: meropenem/vaborbactam, imipenem/relebactam, eravacycline, delafloxacin, improved piperacillin-tazobactam #diagnosticsispower

[U.S. PIRG @uspirg]

@CDCgov now estimates 35K American deaths from #superbugs each year. Tune in at 530 PM EST for more info in the first episode of ‘Superbugs Unplugged’ an antibiotic resistance podcast from @matthewwell and @battlesuperbugs. #USAAW19 #SuperbugsUnplugged

[Tetraphase @Tetraphase]

Tetraphase supports this initiative and knows how great #Pharmacists are at ensuring appropriate abx prescribing and use! #BeAntibioticsAware

[SIDP @SIDPharm]

Pharmacists are antibiotics aware! As you plan activities for U.S. Antibiotic Awareness Week, see what @SIDPharm and @ASHPOfficial recommend to improve antibiotic use #BeAntibioticsAware #USAAW19 https://t.co/Avw7gL0Jth

[Administrator Seema Verma @SeemaCMS]

The challenge of drug-resistant bacteria, or antimicrobial resistance (AMR) has become a public health crisis & access to new antibiotics is limited. So, @CMSGov is firing up the engine of American innovation to battle drug-resistant bacteria. https://t.co/n21n0Nqf6b

[Tetraphase @Tetraphase]

https://t.co/uT1HUFc2JM @GoHealio

[Tetraphase @Tetraphase]

Listen to Tetraphase’s President & CEO, Larry Edwards, discuss recently announced changes to antibiotic reimbursements on the new Contagion® Connect Podcast: https://t.co/rNNhWeFqqu

[Tetraphase @Tetraphase]

An antimicrobial susceptibility study conducted using data from US hospitals included in the BD Insights Research Database demonstrates a high national prevalence of resistant Enterobacteriaceae and Acinetobacter spp., including ESBLs and CRAB. https://t.co/SOp1tFMmBc

[Tetraphase @Tetraphase]

Xerava™️ (eravacycline) is now available on the Thermo Scientific Sensititre AST System, the first FDA-cleared, IVD-labeled microbroth dilution susceptibility plate for comprehensive AST!!
https://t.co/OqrJ0beRRI